	US 11,851,462 B2
	Targeting G3BP aggregation to prevent neurodegeneration
Amar N. Kar, Lexington, SC (US); Pabitra Sahoo, West Columbia, SC (US); Jeffery Twiss, Columbia, SC (US); and Sean McGill, Columbia, SC (US)
Assigned to University of South Carolina, Columbia, SC (US)
Filed by University of South Carolina, Columbia, SC (US)
Filed on May 22, 2020, as Appl. No. 16/881,096.
Claims priority of provisional application 62/876,852, filed on Jul. 22, 2019.
Prior Publication US 2021/0024591 A1, Jan. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/435 (2006.01); C07K 7/08 (2006.01); A61P 25/28 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/435 (2013.01) [A61P 25/28 (2018.01); C07K 7/08 (2013.01); A61K 38/00 (2013.01)]

14 Claims

1. A prophylactic method for blocking stress granule aggregation comprising:

treating at least one cortical neuron cell with a cell permeable polypeptide to reduce neurodegeneration of the at least one cortical neuron cell thereby preventing induced and mediated neurotoxicity via blocking stress granule aggregation by treatment with the cell permeable polypeptide;

wherein the cell permeable polypeptide disassembles aggregates of stress granules and neurodegeneration-associated RNA binding proteins along axons; and

wherein the cell permeable polypeptide is a G3BP1 peptide comprising between 19-21 amino acids.